JP2023521059A - ヒアルロニダーゼの投与による目の損傷の低減又は抑制 - Google Patents

ヒアルロニダーゼの投与による目の損傷の低減又は抑制 Download PDF

Info

Publication number
JP2023521059A
JP2023521059A JP2022560457A JP2022560457A JP2023521059A JP 2023521059 A JP2023521059 A JP 2023521059A JP 2022560457 A JP2022560457 A JP 2022560457A JP 2022560457 A JP2022560457 A JP 2022560457A JP 2023521059 A JP2023521059 A JP 2023521059A
Authority
JP
Japan
Prior art keywords
minutes
hyaluronidase
eye
hyaluronic acid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521059A5 (cg-RX-API-DMAC7.html
Inventor
ヨエリン,スティーブ
Original Assignee
メッド プログレス,エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メッド プログレス,エルエルシー filed Critical メッド プログレス,エルエルシー
Publication of JP2023521059A publication Critical patent/JP2023521059A/ja
Publication of JP2023521059A5 publication Critical patent/JP2023521059A5/ja
Priority to JP2026002581A priority Critical patent/JP2026065067A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
JP2022560457A 2020-04-02 2021-04-02 ヒアルロニダーゼの投与による目の損傷の低減又は抑制 Pending JP2023521059A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026002581A JP2026065067A (ja) 2020-04-02 2026-01-09 ヒアルロニダーゼの投与による目の損傷の低減又は抑制

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004444P 2020-04-02 2020-04-02
US63/004,444 2020-04-02
PCT/US2021/025668 WO2021203062A1 (en) 2020-04-02 2021-04-02 Reducing or inhibiting ocular damage by hyaluronidase administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026002581A Division JP2026065067A (ja) 2020-04-02 2026-01-09 ヒアルロニダーゼの投与による目の損傷の低減又は抑制

Publications (2)

Publication Number Publication Date
JP2023521059A true JP2023521059A (ja) 2023-05-23
JP2023521059A5 JP2023521059A5 (cg-RX-API-DMAC7.html) 2024-04-10

Family

ID=77921064

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560457A Pending JP2023521059A (ja) 2020-04-02 2021-04-02 ヒアルロニダーゼの投与による目の損傷の低減又は抑制
JP2026002581A Pending JP2026065067A (ja) 2020-04-02 2026-01-09 ヒアルロニダーゼの投与による目の損傷の低減又は抑制

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026002581A Pending JP2026065067A (ja) 2020-04-02 2026-01-09 ヒアルロニダーゼの投与による目の損傷の低減又は抑制

Country Status (11)

Country Link
US (1) US11878051B2 (cg-RX-API-DMAC7.html)
EP (1) EP4125928A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023521059A (cg-RX-API-DMAC7.html)
KR (1) KR20230005198A (cg-RX-API-DMAC7.html)
CN (1) CN115697348A (cg-RX-API-DMAC7.html)
AU (1) AU2021248653B2 (cg-RX-API-DMAC7.html)
CA (1) CA3174498A1 (cg-RX-API-DMAC7.html)
IL (1) IL296979A (cg-RX-API-DMAC7.html)
MX (1) MX2022012426A (cg-RX-API-DMAC7.html)
WO (1) WO2021203062A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003755A (es) * 2021-09-25 2024-04-15 Med Progress Llc Reduccion o inhibicion del da?o tisular mediante la administracion de hialuronidasa.
KR102922198B1 (ko) * 2022-04-25 2026-02-03 주식회사 메디팹 조직 수복용 생체재료의 분해 또는 교정용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525022A (ja) * 2010-04-26 2013-06-20 エモリー ユニバーシティ 極微針を使用した、眼組織への薬物送達のための方法および装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504025D0 (en) 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
KR100566451B1 (ko) * 1997-05-22 2006-03-31 이스타 파마슈티칼스, 인크. 안질환 치료에서 초자체액의 액화를 위한 안과용 제제의 제조에 있어서의 히알루로니다제의 용도
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20090311237A1 (en) * 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20120101033A1 (en) 2010-10-05 2012-04-26 Shantha Totada R Retinitis pigmentosa treatment
US11076992B2 (en) 2019-04-19 2021-08-03 Elt Sight, Inc. Methods of transverse placement in ELT

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525022A (ja) * 2010-04-26 2013-06-20 エモリー ユニバーシティ 極微針を使用した、眼組織への薬物送達のための方法および装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Effectiveness of Retrobulbar Hyaluronidase Injection in an Iatrogenic Blindness Rabbit Model Using H", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 144(1), JPN7025000874, July 2019 (2019-07-01), pages 137 - 143, ISSN: 0005682988 *

Also Published As

Publication number Publication date
ZA202211833B (en) 2023-04-26
WO2021203062A1 (en) 2021-10-07
JP2026065067A (ja) 2026-04-14
AU2021248653B2 (en) 2024-05-02
MX2022012426A (es) 2023-01-11
CN115697348A (zh) 2023-02-03
CA3174498A1 (en) 2021-10-07
EP4125928A1 (en) 2023-02-08
US20210308234A1 (en) 2021-10-07
IL296979A (en) 2022-12-01
US11878051B2 (en) 2024-01-23
EP4125928A4 (en) 2024-06-12
AU2021248653A1 (en) 2022-12-01
KR20230005198A (ko) 2023-01-09

Similar Documents

Publication Publication Date Title
Kang-Mieler et al. Advances in ocular drug delivery systems
Cardillo et al. Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery
Kamiya et al. Comparison of Collamer toric contact lens implantation and wavefront-guided laser in situ keratomileusis for high myopic astigmatism
Ciulla et al. Microinjection via the suprachoroidal space: a review of a novel mode of administration.
JP2026065067A (ja) ヒアルロニダーゼの投与による目の損傷の低減又は抑制
Yin et al. Facilitation of amblyopia management by laser in situ keratomileusis in high anisometropic hyperopic and myopic children
Desai et al. Long-term follow-up of hyperopic laser in situ keratomileusis correction using the Star S2 excimer laser
Blumenkranz et al. Fluid-gas exchange and photocoagulation after vitrectomy: indications, technique, and results
Jaffe Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis
Ryoo et al. Regression of iris neovascularization after subconjunctival injection of bevacizumab
US11890331B2 (en) Reducing or inhibiting ocular damage by hyaluronidase administration
Zegarska et al. Management of complications associated with the use of hyaluronic acid fillers. Recommendations of the Aesthetic Dermatology Section of the Polish Dermatological Society
US20240123041A1 (en) Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration
US20250134966A1 (en) Reducing or Inhibiting Tissue Damage Using Hyaluronidase Administration
Sund et al. Clinical Update: FDA Approval of Susvimo™ for Neovascular Age-Related Macular Degeneration
Loy et al. Consensus on the intravitreal injection technique among infants with retinopathy of prematurity by the vitreo-retina society of the Philippines
RU2102953C1 (ru) Способ введения лекарственных препаратов
Kangastupa A New Platform for Suprachoroidal Drug Delivery Using Standard Commercially Available Needles
Sato et al. Transconjunctival Compression Sutures for Postoperative Hypotony After PRESERFLO MicroShunt Revision: A Case Report
RU2196556C2 (ru) Способ лечения органических и функциональных заболеваний сетчатки
Pacella et al. Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection
Slakter et al. Posterior juxtascleral delivery of anecortave acetate for treatment of age-related macular degeneration
WO2022092209A1 (ja) 温度制御により薬効解消可能な眼圧上昇剤
Alkan et al. Inferonasal XEN gel stent implantation in a refractory glaucoma patient with failed multiple glaucoma filtration surgeries: Case report
Beleznay et al. Avoidance and Management of Complications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909